Food - Health

PR Newswire

Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Provisional Approval in New Zealand for Adolescents Aged 12 Through 17

  • Written by PR Newswire
Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Provisional Approval in New Zealand for Adolescents Aged 12 Through 17
  • Nuvaxovid™ is New Zealand's only protein-based COVID-19 vaccine

GAITHERSBURG, Md., Aug. 18, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that New Zealand's Medsafe has granted expanded provisional...

Read more: Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Provisional Approval in New Zealand for...

More Articles ...

  1. Bahrain's Ministry of Electricity and Water Affairs launches tender for 72 MW solar plant
  2. Asian Captive Conference 2022: Onwards And Upwards For The Captive Market
  3. MILKEN INSTITUTE ASIA SUMMIT BRINGS GLOBAL LEADERS TOGETHER IN SINGAPORE SEPTEMBER 28 - 30
  4. Koinly Announces Extended NFT Support
  5. Allianz Trade in Asia Pacific appoints Regional Commercial Director
  6. Delegate Connect Rebrands As Joyn
  7. Announcing the Release of The Disruptors, the First Comprehensive Documentary Film on ADHD Award-Winning, Star-Studded Documentary Available in Australia on Apple TV/iTunes, Google Play, and YouTube
  8. MoF welcomes the IMF Staff's Statement on Article IV Consultation with the Kingdom in 2022.
  9. Skedda Partners with Five Elms Capital to Modernize Space Management and Scheduling
  10. Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Provisional Approval in New Zealand as a First and Second Booster for Adults